Burning Rock Biotech Stock Today
BNR Stock | USD 6.36 0.68 9.66% |
PerformanceOK
| Odds Of DistressHigh
|
Burning Rock is selling at 6.36 as of the 25th of February 2025; that is 9.66 percent decrease since the beginning of the trading day. The stock's lowest day price was 6.32. Burning Rock has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 27th of November 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of June 2020 | Category Healthcare | Classification Health Care |
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the Peoples Republic of China. The company was incorporated in 2014 and is headquartered in Guangzhou, China. Burning Rock operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 8.53 M outstanding shares of which 56.02 K shares are currently shorted by investors with about 11.21 days to cover. More on Burning Rock Biotech
Moving together with Burning Stock
Moving against Burning Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Burning Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Old Names | [Two Shields Investments Plc, Brenntag SE, Burning Rock Biotech Limited] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, DAX Index, HDAX Performance, DAX Price, NASDAQ Composite, NASDAQ Health Care, Healthcare, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBurning Rock can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Burning Rock's financial leverage. It provides some insight into what part of Burning Rock's total assets is financed by creditors.
|
Burning Rock Biotech (BNR) is traded on NASDAQ Exchange in USA. It is located in No. 5, Xingdao Ring Road North, Guangzhou, China, 510005 and employs 786 people. Burning Rock is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 72.22 M. Burning Rock Biotech runs under Biotechnology sector within Health Care industry. The entity has 8.53 M outstanding shares of which 56.02 K shares are currently shorted by investors with about 11.21 days to cover.
Burning Rock Biotech has about 1.15 B in cash with (255.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Burning Rock Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Burning Rock Biotech is $72.22 Million. Over half of Burning Rock's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Burning Ownership Details
Burning Stock Institutional Holders
Instituion | Recorded On | Shares | |
Skyview Investment Advisors, Llc | 2024-09-30 | 10 K | |
Ubs Group Ag | 2024-12-31 | 1.4 K | |
Shen Neil Nanpeng | 2024-12-31 | 885 | |
Bnp Paribas Arbitrage, Sa | 2024-12-31 | 800 | |
Rhumbline Advisers | 2024-12-31 | 580 | |
Jpmorgan Chase & Co | 2024-09-30 | 240 | |
Tower Research Capital Llc | 2024-12-31 | 192 | |
Citigroup Inc | 2024-12-31 | 31.0 | |
Blackrock Inc | 2024-12-31 | 6.0 | |
Kynam Capital Management, Lp | 2024-12-31 | 994.9 K | |
Massachusetts Financial Services Company | 2024-12-31 | 374.4 K |
Burning Rock Historical Income Statement
Burning Stock Against Markets
Burning Rock Corporate Management
Jinxiang Li | Compliance CFO | Profile | |
Yusheng Han | Chairman Founder | Profile | |
Zhihong Zhang | Chief Officer | Profile | |
Shaokun Chuai | Chief Director | Profile | |
Hao Liu | Senior Advisor | Profile | |
Xiaozhi Hu | Senior Finance | Profile |
Additional Tools for Burning Stock Analysis
When running Burning Rock's price analysis, check to measure Burning Rock's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Burning Rock is operating at the current time. Most of Burning Rock's value examination focuses on studying past and present price action to predict the probability of Burning Rock's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Burning Rock's price. Additionally, you may evaluate how the addition of Burning Rock to your portfolios can decrease your overall portfolio volatility.